Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT
Open Access
- 14 January 2021
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (1), 13-16
- https://doi.org/10.1159/000512068
Abstract
We report a 49-year-old male with castration-resistant prostate cancer (CRPC) with oligometastasis diagnosed by 11C-choline positron emission tomography-computed tomography (PET/CT) and treated with target radiotherapy. In the diagnosis of CRPC (serum prostate-specific antigen [PSA] level of 6.53 ng/mL after maximum androgen blockade (MAB) therapy, high-dose brachytherapy, and external beam radiotherapy), 11C-choline PET/CT detected one tiny obturator lymph node metastasis which fluorodeoxyglucose PET/CT could not detect. He underwent intensity-modulated radiation therapy and MAB was restarted. The PSA value decreased and reached nadir (0.091 ng/mL) after 6 months. The time to PSA progression was 10 months. The choline PET/CT finding and the corresponding local treatment could play an important role in the management sequence of oligoprogressive CRPC.Keywords
This publication has 8 references indexed in Scilit:
- Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic FactorInternational Journal of Radiation Oncology*Biology*Physics, 2019
- Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancerInternational Urology and Nephrology, 2019
- Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?European Urology, 2019
- Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyWorld Journal of Urology, 2019
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II TrialJournal of Clinical Oncology, 2018
- Local Therapy Improves Survival in Metastatic Prostate CancerEuropean Urology, 2017
- Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisEuropean Urology, 2016
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal of Clinical Practice, 2011